1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity

Pharmacology and Toxicology

Volumn 92, Issue 2, 2003, Pages 71-80

  Kita, Taizo ^a,b   Saraya, Tutomu ^a   Konishi, Noboru ^a   Matsunari, Yasunori ^a   Shimada, Keiji ^a   Nakamura, Mitsutoshi ^a   O'Hara, Kiichi ^a   Wagner, George C ^c   Nakashima, Toshikatsu ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOMUTILATION; BRAIN PROTECTION; CONTROLLED STUDY; DISEASE MARKER; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; HYPERTHERMIA; IMMUNOREACTIVITY; MALE; METABOLITE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOTHERMIA; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0037293903     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2003.920203.x     Document Type: Article

References (39)

1. Albers, D. S. & P. K. Sonsalla: Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Therap. 1995, 275, 1104-1114.
2. +-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors. Neurosci. Lett. 2001, 314, 82-86.
3. Bowyer, J. F., A. W. Tank, G. D. Newport, W. Slikker, S. F. Ali & R. R. Holson: The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in the rat striatum. J. Pharmacol. Exp. The. 1992, 260, 817-824.
4. Breese, G. R., A. A. Baumeister, T. J. McCown, S. G. Emerick, G. D. Frye, K. Crotty & R. A. Mueller: Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Therap. 1984, 231, 343-354.
5. Burrows, K. B., W. L. Nixdorf & B. K. Yamamoto: Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J. Pharmacol. Exp. Therap. 2000, 292, 853-860.
6. Cadet, J. L., P. Sheng, S. Ali, R. Rothman, E. Carlson & C. Epstein: Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 1994, 62, 380-383.
7. Chance, M. R. A.: Factors influencing the toxicity of sympathomimetic amines to solitary mice. J. Pharmacol. Exp. Therap. 1947, 89, 289-296.
8. Cubells, J. F., S. Rayport, G. Rajendran & D. Sulzer: Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 1994, 14, 2260-2271.
9. De Vito, M. J & G. C. Wagner: Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989, 28, 1145-1150.
10. + administered centrally in mice. Neuropharmacology 1997, 36, 993-997.
11. Franklin, K. B. & G. T. Paxinos: The mouse brain in stereotaxic coordinates. Academic Press, New York, 1986.
12. +induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 1995, 688, 161-170.
13. Fumagalli, F., R. R. Gainetdinov, K. J. Valenzano & M. G. Caron: Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 1998, 18, 4861-4869.
14. Fumagalli, F., R. R. Gainetdinov, Y. M. Wang, K. J. Valenzano, G. W. Miller & M. G. Caron: Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 1999, 19, 2424-2431.
15. Gibb, J.W & F.J. Kogan: Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch. Pharmacol. 1979, 310, 185-187.
16. Giovanni, A., L. P. Liang, T. G. Hastings & M. J. Zigmond: Estimating hydroxy radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 1995, 64, 1819-1825.
17. Hamre, K., R. Tharp, K. Pooh, X. Xiong & R. J. Smeyne: Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 1999, 828, 91-103.
18. Javitch, J. A., R. J. D'Amato, S.M. Strittmatter & S. H. Snyser: Parkinsonism-inducing neurotoxin-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity: Uptake of the metabolite N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Proc. Nat. Acad. Sci. 1985, 82, 2173-2177.
19. Itzhak, Y., J. L. Martin, S. F. Ali & M. D. Norenberg: Depletion of striatal dopamine transporter does not effect psychostimulant-induced locomotor activity. Neuroreport 1997, 8, 3245-3249.
20. Kelly, P. H., P. W. Seviour & S. D. Iversen: Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 1975, 94, 507-522.
21. Kita, T., G. C. Wagner, M. A. Philbert, L. A. King & H. E. Lowndes: Effects of pargyline and pyrogallol on methamphetamine-induced dopamine depletion. Mol. Chem. Neuropath. 1995, 24, 31-41.
22. Kita, T., S. Paku, M. Takahashi, K. Kubo, G. C. Wagner & T. Nakashima: Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice. Neuropharmacology 1998, 37, 1177-1184.
23. Kita, T., M. Takahashi, K. Kubo, G. C. Wagner & T. Nakashima: Hydroxyl radical formation following methamphetamine administration to rats. Pharmacology & Toxicology 1999, 85, 133-137.
24. Kita, T., Y. Matsunari, T. Saraya, K. O. Shimada, K. O'Hara, K. Kubo, G. C. Wagner & T. Nakashima: Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int. J. Dev. Neurosci. 2000a, 18, 521-530.
25. Kita, T., Y. Matsunari, T. Saraya, K. Shimada, K. O'Hara, K. Kubo, G.C. Wagner & T. Nakashima: Evaluation of the effects of α-phenyl-n-tert-butyl nitorone pretreatment on neurobehavioral effects of methamphetamine. Life Sci. 2000b, 67, 1559-1571.
26. Liu, Y. & R. H. Edwards: The role of vesicular transport proteins in synaptic transmission and neural degeneration. Ann. Rev. Neurosci. 1997, 20, 125-156.
27. Mayer, R. A., M. F. Jarvis & G. C. Wagner: Cocaine blocks the dopamine depletion induced by 1methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Res. Comm. Chem. Path. Pharmacol. 1985, 49, 145-148.
28. Miller, D. B. & J. P. O'Callaghan: Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Therap. 1994, 270, 752-760.
29. Ricaurte, G. A., R. W. Guillery, L. S. Seiden, C. R. Schuster & R.Y. Moore: Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 1982, 235, 93-103.
30. Ricaurte, G. A., R. W. Fuller, K. W. Perry, L. S. Seiden & C. R. Schuster: Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of D-methamphetamine and D-amphetamine. Neuropharmacology 1983, 22, 1165-1169.
31. Schroeder, U., M. R. Kreutz, H. Schroeder & B. A. Sabel: Amphetamine induces hyper motility in MPTP-lesioned mice. Pharmacol. Biochem. Behav. 1997, 56, 281-285.
32. Seiden, L. S. & G. Vosmer: Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methamphetamine. Pharmacol. Biochem. Behav. 1984, 21, 29-31.
33. Seiden, L. S., K. E. Sabol & G. A. Ricaurte: Amphetamine: effects on catecholamine systems and behavior. Ann. Rev. Pharmacol. Tox. 1993, 32, 639-677.
34. Sonsalla, P. K. & R. E. Heikkila: Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuropsychopharmacol. Biol. Psych. 1988, 12, 345-354.
35. Sundström, E., I. Stromberg, T. Tsutsumi, L. Olson & G. Jonsson: Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987, 405, 26-38.
36. Sziráki, I., V. Kardos, M. Patthy, M. Ptfalusi & G. Budai: Methamphetamine protects against MPTP neurotoxicity in C57BL mice. Eur. J. Pharmacol. 1994, 251, 311-314.
37. Wagner, G. C., G. A. Ricaurte, L. S. Seiden, C. R. Schuster, R. J. Miller & J. Westley: Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980, 181, 151-160.
38. Wagner, G. C., J. Lucot, C. R. Schuster & L. S. Seiden: α-Methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 1983, 270, 285-288.
39. Xie, T., U. D. McCann, S. Kim, J. Yuan & G. A. Ricaurte: Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 2000, 20, 7838-7845.